MétaCan
Menu
Back to cohort
Record W3164716110 · doi:10.1002/ejhf.2248

Risk and risk reduction in trials of heart failure with reduced ejection fraction: absolute or relative?

2021· article· en· W3164716110 on OpenAlexaff
Harriette G.C. Van Spall, Tauben Averbuch, Kevin Damman, Adriaan A. Voors

Bibliographic record

VenueEuropean Journal of Heart Failure · 2021
Typearticle
Languageen
FieldMedicine
TopicHeart Failure Treatment and Management
Canadian institutionsImpactPopulation Health Research InstituteMcMaster University
Fundersnot available
KeywordsMedicinePopulationLibrary scienceEnvironmental health

Abstract

fetched live from OpenAlex

Randomized clinical trials (RCTs) of heart failure with reduced ejection fraction (HFrEF) typically recruit patients at high risk of clinical outcomes during the follow-up period by including those with severe symptoms, comorbidities, elevated cardiac biomarkers, or a recent hospitalization. 1 By recruiting patients who will likely respond to the intervention and commonly experience outcomes without it, trials can demonstrate treatment efficacy with smaller sample sizes or shorter periods of follow-up.For example, in the CONSENSUS RCT of enalapril in patients with severe symptoms, 253 enrolled patients demonstrated a 40% relative risk reduction (RRR) in 6-month mortality.2 In contrast, in the SOLVD trial of enalapril in younger patients with less severe symptoms, 2569 patients were enrolled to demonstrate a 16% RRR in 4-year mortality 3 (Table 1).Some have argued that recruiting high-risk patients in an RCT can have drawbacks -patients may be too advanced in their disease trajectory for treatment to improve physiologic and clinical endpoints.4 Another concern is that higher-risk patients may experience adverse effects more commonly.The VICTO-RIA trial showed that vericiguat caused a 10% RRR [hazard ratio (HR) 0.90; 95% confidence interval (CI) 0.82, 0.98] in the composite endpoint of cardiovascular death or heart failure hospitalization.5 VICTORIA enrolled higher-risk patients (37.8 events/100 patient-years) than a majority of pharmacotherapy trials in patients with HFrEF, a reason proposed by some to explain its modest effect; the absolute risk reduction (ARR) (3.0%) and RRR were lower than in the PARADIGM-HF trial, which recruited lower-risk patients (13.2 events/100 patient-years) and demonstrated that sacubitril-valsartan caused a RRR of 20% (HR 0.80; 95% CI 0.73, 0.87) and ARR of 4.7 vs. enalapril on the same composite endpoint.6 Furthermore, subgroup analysis in a few HFrEF trials demonstrated the possibility of attenuated treatment effect in higher-risk patients.[6][7][8] To some, this evidence represents the possibility of a risk threshold within RCTs beyond which pharmacotherapies may provide minimal incremental benefit.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.098
metaresearch head score (Gemma)0.159
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Commentary · Consensus signal: none
Teacher disagreement score0.098
Threshold uncertainty score0.518

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0980.159
Meta-epidemiology (narrow)0.0030.002
Meta-epidemiology (broad)0.0130.015
Bibliometrics0.0030.003
Science and technology studies0.0010.003
Scholarly communication0.0050.006
Open science0.0020.002
Research integrity0.0060.009
Insufficient payload (model declined to judge)0.0090.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.027
GPT teacher head0.285
Teacher spread0.258 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations17
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Journal of Heart FailureSame topicHeart Failure Treatment and ManagementFrench-language works237,207